PY0117895A - Derivados de imidazol - Google Patents
Derivados de imidazolInfo
- Publication number
- PY0117895A PY0117895A PY200100117895A PY0117895A PY0117895A PY 0117895 A PY0117895 A PY 0117895A PY 200100117895 A PY200100117895 A PY 200100117895A PY 0117895 A PY0117895 A PY 0117895A PY 0117895 A PY0117895 A PY 0117895A
- Authority
- PY
- Paraguay
- Prior art keywords
- derivatives
- imidazole derivatives
- present
- iminazole
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
La presente invencion se refiere a derivados de iminazol, a composiciones farmaceuticas que comprenden tales derivados y a procedimientos de uso de tales derivados para tratar el crecimiento celular anormal y ciertas,enfermedades y afecciones del sistema nervioso central. Los compuestos de la presente invencion actuan como inhibidores de las enzimas proteina quinasas...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY0117895A true PY0117895A (es) | 2003-11-03 |
Family
ID=22829075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY200100117895A PY0117895A (es) | 2000-07-31 | 2001-07-23 | Derivados de imidazol |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1305295A1 (es) |
| JP (2) | JP4166084B2 (es) |
| KR (1) | KR20030019644A (es) |
| CN (1) | CN1444567A (es) |
| AP (1) | AP2001002232A0 (es) |
| AR (1) | AR032629A1 (es) |
| AU (1) | AU2001270944A1 (es) |
| BG (1) | BG107469A (es) |
| BR (1) | BR0112862A (es) |
| CA (1) | CA2418115A1 (es) |
| CR (1) | CR6861A (es) |
| CZ (1) | CZ2003225A3 (es) |
| DO (1) | DOP2001000220A (es) |
| EA (1) | EA200300097A1 (es) |
| EC (1) | ECSP034445A (es) |
| EE (1) | EE200300049A (es) |
| GT (1) | GT200100147A (es) |
| HR (1) | HRP20030048A2 (es) |
| HU (1) | HUP0303069A3 (es) |
| IL (1) | IL153787A0 (es) |
| IS (1) | IS6662A (es) |
| MA (1) | MA26932A1 (es) |
| MX (1) | MXPA03000939A (es) |
| NO (1) | NO20030472L (es) |
| NZ (1) | NZ523272A (es) |
| OA (1) | OA12345A (es) |
| PA (1) | PA8523701A1 (es) |
| PE (1) | PE20020337A1 (es) |
| PL (1) | PL365134A1 (es) |
| PY (1) | PY0117895A (es) |
| SK (1) | SK1042003A3 (es) |
| SV (1) | SV2002000571A (es) |
| TN (1) | TNSN01114A1 (es) |
| UY (1) | UY26862A1 (es) |
| WO (1) | WO2002010141A1 (es) |
| ZA (1) | ZA200300819B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| CA2487948A1 (en) | 2002-06-14 | 2003-12-24 | Applied Research Systems Ars Holding N.V. | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| DE10233817A1 (de) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| ATE399155T1 (de) | 2004-03-23 | 2008-07-15 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
| PT1791811E (pt) | 2004-09-21 | 2010-02-23 | Astellas Pharma Inc | ¿derivados de aminoálcool |
| US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| BRPI0616141A2 (pt) * | 2005-09-22 | 2011-06-07 | Pfizer Prod Inc | compostos imidazol para o tratamento de distúrbios neurológicos |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CN101421265A (zh) | 2006-01-18 | 2009-04-29 | 安姆根有限公司 | 作为蛋白激酶b(pkb)抑制剂的噻唑化合物 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US8642598B2 (en) * | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| US8455648B2 (en) * | 2008-04-24 | 2013-06-04 | Abbott Gmbh & Co. Kg | 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| AU2013355054B2 (en) | 2012-12-07 | 2017-08-24 | Chemocentryx, Inc. | Diazole lactams |
| US9169248B2 (en) * | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
| US10653672B2 (en) | 2014-02-07 | 2020-05-19 | National University Corporation Tokyo Medical And Dental University | Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator |
| CA3208241A1 (en) * | 2015-08-31 | 2017-03-09 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
| GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| IL261998B2 (en) | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| CN110963996B (zh) * | 2017-10-25 | 2022-09-09 | 西南大学 | 含苯乙酮取代基的靛红唑醇类化合物及其制备方法和医药应用 |
| WO2020010155A1 (en) * | 2018-07-03 | 2020-01-09 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| PL4010322T3 (pl) | 2019-08-09 | 2026-02-16 | Pfizer Inc. | Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| US20240132485A1 (en) * | 2020-10-16 | 2024-04-25 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| CN112250636A (zh) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-氨基咪唑类化合物及其合成方法 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| TWI905452B (zh) | 2021-09-01 | 2025-11-21 | 美商斯普林渥克斯治療有限公司 | 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成 |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| CN116983313B (zh) * | 2023-07-13 | 2026-01-27 | 四川大学 | Nu6300的新用途 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| US6417185B1 (en) * | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-23 PY PY200100117895A patent/PY0117895A/es unknown
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Ceased
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 EE EEP200300049A patent/EE200300049A/xx unknown
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/xx not_active Application Discontinuation
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY0121331A (es) | Derivados de pirazol | |
| CR9677A (es) | Derivados de pirrolo(2,3-b) piridina como inhibidores de proteina cinasa | |
| SV2003001148A (es) | Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv | |
| UY27811A1 (es) | 3-aminopirazoles n-sustituidos como inhibidores para el tratamiento de los desórdenes proliferativos de las células. | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| BRPI0514537A (pt) | compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase | |
| BRPI0513915A (pt) | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase | |
| PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| DOP2004000949A (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| SV2008002365A (es) | Compuestos de quinolina heteroaromaticos ref. pc32593a | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| CL2011001360A1 (es) | Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro. | |
| BRPI0514750A (pt) | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase | |
| BRPI0117360B8 (pt) | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos | |
| SV2006002175A (es) | Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a | |
| ECSP077994A (es) | Aminopirimidinas como moduladores de cinasa | |
| CR10560A (es) | Inhibidores de tirosina quinasa | |
| DOP2005000251A (es) | 3-amino-pirazol [3,4b] piridinas como inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento. | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| ECSP078017A (es) | Inhibidores de tirosina quinasa | |
| CR8546A (es) | DERIVADOS DE 1H-TIENO [2,3c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA | |
| BR0009561A (pt) | 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase |